A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : DME / diabetic macular edema

[Related PubMed/MEDLINE]
Total Number of Papers: 1363
[Display Entries]
100 entries :
     (Publication year, Descending)
100 entries :
     (Publication year, Ascending)
>> all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   DME  (>> Co-occurring Abbreviation)
Long Form:   diabetic macular edema
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2019 A Comparison Study of Ranibizumab and Aflibercept in Patients with Naive Diabetic Macular Edema in Presence of Serous Retinal Detachment. BCVA, CMT, SRD, SRDH
2019 A Novel Biomarker in Diabetic Macular Edema with Serous Retinal Detachment: Serum Chitinase-3-Like Protein 1. CHI3L1, CMO, DRT, IL-6, SD-OCT, SRD
2019 Accuracy of Detection and Grading of Diabetic Retinopathy and Diabetic Macular Edema Using Teleretinal Screening. DFE, DR, TRI
2019 Adherence to Intravitreal Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Drugs in Diabetic Macular Edema in an Egyptian Population: A Health Belief Model. Anti-VEGF, HBM
2019 Analysis of quantitative correlations between microaneurysm, ischaemic index and new vessels in ultrawide-field fluorescein angiography images using automated software. MA, UWFFA
2019 Anatomic Response to Intravitreal Dexamethasone Implant and Baseline Aqueous Humor Cytokine Levels in Diabetic Macular Edema. AH, CI, CMT, DEX, DRT, IL, IP, MCP, MV, OCT, SD, TNF, VEGF
2019 Anti-Fumarase Antibody as a Predictor of Functional Efficacy of Anti-VEGF Therapy for Diabetic Macular Edema. CSF, EZ, OCT, VA
2019 Anti-Hexokinase 1 Antibody as a Novel Serum Biomarker of a Subgroup of Diabetic Macular Edema. DR
2019 Anti-VEGF Therapy for Diabetic Retinopathy: Consequences of Inadvertent Treatment Interruptions. NPDR, VA
10  2019 Aqueous Humor Cytokines and Long-Term Response to Anti-Vascular Endothelial Growth Factor Therapy in Diabetic Macular Edema. VEGF
11  2019 Artificial Intelligence in Diabetic Eye Disease Screening. AI, DL, DR, OCT
12  2019 Asia-Pacific Technology and Trend Survey 2016-2017. VEGF
13  2019 Automatic Choroid Layer Segmentation from Optical Coherence Tomography Images Using Deep Learning. BM, OCT
14  2019 Baseline Ocular Characteristics of Patients Undergoing Initiation of Anti-Vascular Endothelial Growth Factor Therapy for Diabetic Macular Edema. CAT, CST, ETDRS, PDR, SRF, VA
15  2019 Characterization of the Systemic Findings of Patients Undergoing Initiation of Anti-Vascular Endothelial Growth Factor Therapy for Diabetic Macular Edema in Routine Clinical Practice. VA, VEGF
16  2019 Classification of Regions of Nonperfusion on Ultra-widefield Fluorescein Angiography in patients with Diabetic Macular Edema. CMT, MV, NPR, UWFFA
17  2019 Clinical preferences and trends of anti-vascular endothelial growth factor treatments for diabetic macular edema in Japan. VEGF
18  2019 Comparative effectiveness and harms of intravitreal antivascular endothelial growth factor agents for three retinal conditions: a systematic review and meta-analysis. BCVA, NVAMD, RVO, VEGF
20  2019 Comparison of the Efficacy of Sub-Tenon versus Intravitreal Triamcinolone Acetonide Injection during Cataract Surgery for Diabetic Macular Edema. BCVA, CS, IVTA, STTA
21  2019 Connexin43 hemichannel block protects against retinal pigment epithelial cell barrier breakdown. BRB, DR, HG, LDH, RPE, TEER
22  2019 Convolutional Mixture of Experts Model: A Comparative Study on Automatic Macular Diagnosis in Retinal Optical Coherence Tomography Imaging. AMD, AUC, CMoE, MCME, ME-CNN, WCME
23  2019 Deep Learning Predicts OCT Measures of Diabetic Macular Thickening From Color Fundus Photographs. AUC, CFPs, CFT, CI, CST, DL, MT, OCT, TD-OCT
24  2019 Dexamethasone for unresponsive diabetic macular oedema: optical coherence tomography biomarkers. BCVA, CMT, DEX, HRS, OCT, SND
26  2019 Diabetic retinopathy, a vascular and inflammatory disease: Therapeutic implications. anti-VEGF, DR, NSAIDs, RAS
27  2019 Diagnostic Accuracy of Digital Retinal Fundus Image Analysis in Detecting Diabetic Maculopathy in Type 2 Diabetes Mellitus. DR, DRFI, ETDRS, ICDR, MGS, OCT, UKNSC
28  2019 Difference in Treatment Effect Between Intravitreal Aflibercept Injection and Laser by Baseline Factors in Diabetic Macular Edema. BCVA, IAI, LS
29  2019 Dose-response analysis of ranibizumab as-needed regimens for visual improvement in patients with diabetic macular edema using a modelling approach. BCVA, ETDRS
30  2019 Durability of Diabetic Retinopathy Improvement with As-Needed Ranibizumab: Open-Label Extension of RIDE and RISE Studies. DR, OLE, PRN
31  2019 Effect of Initial Management With Aflibercept vs Laser Photocoagulation vs Observation on Vision Loss Among Patients With Diabetic Macular Edema Involving the Center of the Macula and Good Visual Acuity: A Randomized Clinical Trial. CI-DME
32  2019 Effect of intravitreal aflibercept treatment on retinal vessel parameters in diabetic macular edema: Arteriolar vasoconstriction. AVR, BCVA, CMT, CRAE, CRVE, IVA, SFCT
33  2019 Effect of Leaking Foveal Microaneurysms on the Treatment of Center-Involving Diabetic Macular Edema: A Pilot Study. BCVA, CMT, IVR, MAs
34  2019 Effect of ripasudil on diabetic macular edema. FT, IOP, ROCK, VA
35  2019 Effectiveness and Safety of Intravitreal Dexamethasone Implant (Ozurdex) in Patients with Diabetic Macular Edema: A Real-World Experience. BCVA, CRT, IOP
36  2019 Efficacy and safety of ranibizumab 0.5 mg in Chinese patients with visual impairment due to diabetic macular edema: results from the 12-month REFINE study. BCVA, PRN
38  2019 Efficacy of vitrectomy combined with an intraoperative dexamethasone implant in refractory diabetic macular edema. CMT
40  2019 Evaluation of outer retinal tubulations in diabetic macular edema underwent anti-VEGF treatment. BCVA, INL, ONL, OPL, ORTs, SD-OCT, VEGF
41  2019 Experiences and perceptions of patients undergoing treatment and quality of life impact of diabetic macular edema: a systematic review. CASP, QOL, VEGF
42  2019 Factors Associated With Visual Acuity and Central Subfield Thickness Changes When Treating Diabetic Macular Edema With Anti-Vascular Endothelial Growth Factor Therapy: An Exploratory Analysis of the Protocol T Randomized Clinical Trial. anti-VEGF, AUC, OCT, PRP, VA
43  2019 Fully automated detection of retinal disorders by image-based deep learning. AMD, anti-VEGF, OCT, ROC, VGG-16
44  2019 Function-first ligandomics for ocular vascular research and drug target discovery. AMD, PDR, VEGF
45  2019 Healthcare Utilization and Treatment Patterns in Diabetic Macular Edema in Korea: a Retrospective Chart Review. VA, VEGF
46  2019 How do we evaluate the role of focal/grid photocoagulation in the treatment of diabetic macular edema? ---
47  2019 Impact of ranibizumab on visual impairment in patients with bilateral diabetic macular edema. IVR, VA
48  2019 Indocyanine green angiography-guided focal navigated laser photocoagulation for diabetic macular edema. BCVA, CRT, FA, ICGA, MAs, MV
49  2019 Inflammatory mediators in the vitreal reflux of patients with diabetic macular edema. CRT, ELISA, IL-6, ONL/RPE, SD-OCT, VR, WB
50  2019 Intravitreal dexamethasone implant Ozurdex in naive and refractory patients with different subtypes of diabetic macular edema. BCVA, CMT, DEX 0.7, ETDRS, OCT
51  2019 Long-term outcomes after intravitreal dexamethasone treatment in steroid responders. IOP
52  2019 Longitudinal Retinal Perfusion Status in Eyes with Diabetic Macular Edema Receiving Intravitreal Aflibercept or Laser in VISTA study. IAI, RNP
53  2019 Loss to Follow-up After Intravitreal Anti-Vascular Endothelial Growth Factor Injections in Patients with Diabetic Macular Edema. AGI, LTFU, NPDR, OR, VEGF
54  2019 Mitochondrial haplogroups are not associated with diabetic retinopathy in a large Australian and British Caucasian sample. NPDR, PDR, PDR
55  2019 Modeling a Telemedicine Screening Program for Diabetic Retinopathy in Iran and Implementing a Pilot Project in Tehran Suburb. DR, GPs, IDS, IRTOS
56  2019 Navigated laser in diabetic macular edema: the impact of reduced injection burden on patients and physicians-who wins and who loses? VEGF
57  2019 One-Year Results of Using a Treat-and-Extend Regimen without a Loading Phase with Anti-VEGF Agents in Patients with Treatment-Naive Diabetic Macular Edema. BCVA, CRT, VEGF
58  2019 Outcome and Predictors for 2-Year Visual Acuity in Eyes with Diabetic Macular Edema Treated with Ranibizumab. BCVA, EZ, IR, MA, PRN, PVD, VA, VMT
59  2019 Pathological Perturbations in Diabetic Retinopathy: Hyperglycemia, AGEs, Oxidative Stress and Inflammatory Pathways. DR, PDR
60  2019 Phase II/III Clinical Trial of Sub-Tenon Injection of Triamcinolone Acetonide (WP-0508ST) for Diabetic Macular Edema. CMT
61  2019 Posterior segment drug delivery for the treatment of exudative age-related macular degeneration and diabetic macular oedema. AMD
62  2019 Profile of a population-based diabetic macular oedema study: the Liverpool Eye and Diabetes Study (Sydney). LEADS, OCT
63  2019 Quantitative Assessment of Outer Retinal Layer and Photoreceptor Outer Segment Layer and Their Relation to Visual Acuity in Diabetic Macular Edema. BCVA, CMT, ORL, PROS
64  2019 Ranibizumab for the Treatment of Diabetic Macular Oedema in the Real-World Clinical Setting in Portugal: A Multicentre Study. BCVA, CMT, NHS
65  2019 Real-world outcomes of observation and treatment in diabetic macular edema with very good visual acuity: the OBTAIN study. CST, VA
66  2019 Real-World Outcomes with Ranibizumab 0.5 mg in Patients with Visual Impairment due to Diabetic Macular Edema: 12-Month Results from the 36-Month BOREAL-DME Study. BCVA, CI, CSFT
67  2019 Retinal Microvasculature and Visual Acuity after Intravitreal Aflibercept in Diabetic Macular Edema: An Optical Coherence Tomography Angiography Study. DCP, FAZ, OCTA, SCP
68  2019 Retinopathy and RAAS Activation: Results From the Canadian Study of Longevity in Type 1 Diabetes. Ang II, NPDR, PDR, RAAS
69  2019 Sensitivity and Specificity of Smartphone-Based Retinal Imaging for Diabetic Retinopathy: A Comparative Study. CI, DR, FOP, NPDR, PDR
70  2019 Sequential Dexamethasone and Aflibercept Treatment in Patients with Diabetic Macular Edema: Structural and Functional Outcomes at 52 Weeks. BCVA, CMT
71  2019 Serum and aqueous humor vitamin D levels in patients with diabetic macular edema. AH
72  2019 Short-term effects of intravitreal bevacizumab in contrast sensitivity of patients with diabetic macular edema and optimizing glycemic control. BCVA, CMT, CS, OCT
73  2019 Simultaneous Inhibition of Angiopoietin-2 and Vascular Endothelial Growth Factor-A with Faricimab in Diabetic Macular Edema: BOULEVARD Phase 2 Randomized Trial. BCVA, CST, DRSS, ETDRS, VEGF-A
74  2019 Switching to Aflibercept in Diabetic Macular Edema after Unsatisfactory Response to Other Anti-vascular Endothelial Growth Factor Drugs. anti-VEGF, logMAR
75  2019 Systemic pharmacokinetic/pharmacodynamic analysis of intravitreal aflibercept injection in patients with retinal diseases. IAI, nAMD
76  2019 The Burden of Macular Diseases in Central and Eastern Europe-Implications for Healthcare Systems. CEE, wAMD
77  2019 The impact of anti-vascular endothelial growth factor agents on visual impairment/blindness prevention in patients with diabetic macular edema and on associated patient and caregiver burden in Japan. ETDRS, SVI, VEGF
78  2019 The impact of intravitreal dexamethasone implant (Ozurdex) on retrobulbar hemodynamics in patients with diabetic macular edema and retinal vein occlusions. CDU, CRA, EDV, OA, PCA, PI, PSV, RI, RVO
79  2019 The Role of Steroids in the Management of Diabetic Macular Edema. IOP, VEGF
80  2019 The USER Study: A Chart Review of Patients Receiving a 0.2g/day Fluocinolone Acetonide Implant for Diabetic Macular Edema. CST, ETDRS, FAc, IOP, OCT, VA
81  2019 Three-dimensional analysis of morphologic changes and visual outcomes in diabetic macular edema. BCVA, DRIL, ELM, EZ, INL, IRF, ONL, OPL, SRF
82  2019 Three-year results from the Retro-IDEAL study: Real-world data from diabetic macular edema (DME) patients treated with ILUVIEN (0.19 mg fluocinolone acetonide implant). BRVA, FAc, IOP, VEGF
83  2019 Toronto tele-retinal screening program for detection of diabetic retinopathy and macular edema. DR, OCT
84  2019 Treatment outcomes and predicting factors for diabetic macular edema treated with ranibizumab - One-year real-life results in Taiwan. BCVA, CFT
85  2019 TRPV4 inhibition prevents increased water diffusion and blood-retina barrier breakdown in the retina of streptozotocin-induced diabetic mice. ADC, BRB, DW-MRI, STZ, TRPV4
86  2019 Vitrectomy for Diabetic Macular Edema: Optical Coherence Tomography Criteria and Pathology of the Vitreomacular Interface. ERM, ILM, SD-OCT, tVC, VMI
87  2019 Vitreous and intraretinal macular changes in diabetic macular edema with and without tractional components. ILM, PPV
88  2019 Vitreous IL-8 and VEGF levels in diabetic macular edema with or without subretinal fluid. IL-8, VEGF
89  2019 Yearly Treatment Patterns for Patients with Recently Diagnosed Diabetic Macular Edema. PPP, VEGF
90  2018 A CCR2/5 Inhibitor, PF-04634817, Is Inferior to Monthly Ranibizumab in the Treatment of Diabetic Macular Edema. BCVA, CI
91  2018 A meta-analysis of the effect of a dexamethasone intravitreal implant versus intravitreal anti-vascular endothelial growth factor treatment for diabetic macular edema. BCVA, CST, DEX, MD, RevMan, VEGF
92  2018 A noninterventional study to monitor patients with diabetic macular oedema starting treatment with ranibizumab (POLARIS). CRT, POLARIS, VA, VAS
93  2018 A novel and less invasive technique to assess cytokine profile of vitreous in patients of diabetic macular oedema. HR-PDR, VR
94  2018 A Pathogenetic Classification of Diabetic Macular Edema. BCVA, CRT, HF, OCT
95  2018 A Prospective Randomized Comparative Dosing Trial of Ranibizumab In Bevacizumab-Resistant Diabetic Macular Edema: The REACT Study. BCVA, CST, ETDRS, TAE
96  2018 A review on recent drug delivery systems for posterior segment of eye. AMD, CMV, DR, RP, RVO
97  2018 A supervised joint multi-layer segmentation framework for retinal optical coherence tomography images using conditional random field. AMD, CRF, OCT, U-BLE
98  2018 Aflibercept for clinically significant diabetic macular edema: 12-month results in daily clinical practice. BCVA, ETDRS
99  2018 Aflibercept in diabetic macular edema refractory to previous bevacizumab: outcomes and predictors of success. CMT, VA
100  2018 An efficacy comparison of anti-vascular growth factor agents and laser photocoagulation in diabetic macular edema: a network meta-analysis incorporating individual patient-level data. BCVA, CrI, ETDRS, IPD, IVT-AFL, NMA, OR, VEGF